In a discovery that could guide the development of next-generation antidepressants and antipsychotic medications, researchers at the Icahn School of Medicine at Mount Sinai have developed new insights ...
In a discovery that could guide the development of next-generation antidepressants and antipsychotic medications, researchers at the Icahn School of Medicine at Mount Sinai have developed new insights ...
Researchers at the Icahn School of Medicine at Mount Sinai have shed valuable light on the complex mechanisms by which a class of psychedelic drugs binds to and activates serotonin receptors to ...
Serotonin 1A receptor is a G protein-coupled receptor of the serotonergic system expressed both presynaptically as an autoreceptor in raphe nuclei and postsynaptically across limbic and cortical ...
Activation of the serotonin receptor, 5-HT1A, has been shown to regulate mood and cognition. The receptor is the primary target of buspirone, vilazodone, and gepirone, FDA-approved medications for the ...
Mindset Pharma Inc. has patented new indoline derivatives acting as 5-HT1A receptor agonists and thus reported to be useful for the treatment of neurological and psychiatric disorders.
Suven Life Sciences Ltd. has identified 5-HT1A receptor agonists and 5-HT2A receptor antagonists reported to be useful for the treatment of depression, insomnia, schizophrenia, bipolar and cognitive ...
In a discovery that could guide the development of next-generation antidepressants and antipsychotic medications, researchers at the Icahn School of Medicine at Mount Sinai have developed new insights ...
Mount Sinai researchers took detailed pictures of the serotonin receptor and clinically-validated drug target 5-HT1A using cryo-electron microscopy to show how the psychedelics LSD and 5-MeO-DMT and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results